NEW DELHI : In another potential boost to availability of robust covid-19 vaccines in India, Novavax early Friday announced its interim phase-3 results showing that its protein subunit jabs have an efficacy of 89.3% against the novel coronavirus.More importantly, the efficacy results of the vaccine come from a trial in UK and South Africa, where two more transmissible strains are more prevalent, indicating that the vaccine provides protection against them.Also Read | Covid vaccination faces slow start“NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants," Novavax president and chief executive.